Analysts forecast that Sanofi SA (NYSE:SNY) will announce earnings per share of $0.98 for the current fiscal quarter, according to Zacks Investment Research. Zero analysts have issued estimates for Sanofi’s earnings, with the lowest EPS estimate coming in at $0.95 and the highest estimate coming in at $1.02. Sanofi posted earnings per share of $1.00 in the same quarter last year, which would indicate a negative year over year growth rate of 2%. The firm is scheduled to issue its next quarterly earnings results before the market opens on Wednesday, October 31st.
According to Zacks, analysts expect that Sanofi will report full-year earnings of $3.14 per share for the current financial year, with EPS estimates ranging from $3.13 to $3.15. For the next financial year, analysts expect that the company will report earnings of $3.28 per share, with EPS estimates ranging from $3.20 to $3.34. Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of analysts that follow Sanofi.
Sanofi (NYSE:SNY) last announced its earnings results on Tuesday, July 31st. The company reported $0.74 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.72 by $0.02. The business had revenue of $8.18 billion during the quarter, compared to the consensus estimate of $8.27 billion. Sanofi had a return on equity of 23.77% and a net margin of 10.29%. The business’s quarterly revenue was down 5.6% on a year-over-year basis. During the same period in the prior year, the company posted $1.35 EPS.
Shares of SNY stock traded down $0.79 during trading hours on Friday, hitting $42.89. 1,909,357 shares of the company’s stock were exchanged, compared to its average volume of 1,896,109. The company has a debt-to-equity ratio of 0.40, a current ratio of 1.22 and a quick ratio of 0.85. The company has a market cap of $112.04 billion, a price-to-earnings ratio of 13.70, a PEG ratio of 2.40 and a beta of 0.82. Sanofi has a fifty-two week low of $37.43 and a fifty-two week high of $50.04.
In related news, major shareholder Sanofi sold 104,552 shares of the stock in a transaction on Thursday, September 6th. The stock was sold at an average price of $406.68, for a total value of $42,519,207.36. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. 1.00% of the stock is currently owned by corporate insiders.
Hedge funds and other institutional investors have recently bought and sold shares of the stock. Fisher Asset Management LLC grew its holdings in Sanofi by 3.6% in the 2nd quarter. Fisher Asset Management LLC now owns 15,622,562 shares of the company’s stock valued at $625,059,000 after buying an additional 549,110 shares in the last quarter. BlackRock Inc. grew its holdings in Sanofi by 0.7% in the 2nd quarter. BlackRock Inc. now owns 3,328,180 shares of the company’s stock valued at $133,161,000 after buying an additional 22,425 shares in the last quarter. Brandes Investment Partners LP grew its holdings in Sanofi by 5.0% in the 2nd quarter. Brandes Investment Partners LP now owns 2,851,133 shares of the company’s stock valued at $114,074,000 after buying an additional 136,316 shares in the last quarter. Northern Trust Corp grew its holdings in Sanofi by 2.3% in the 2nd quarter. Northern Trust Corp now owns 2,209,626 shares of the company’s stock valued at $88,407,000 after buying an additional 49,233 shares in the last quarter. Finally, Hamlin Capital Management LLC grew its holdings in Sanofi by 16.7% in the 2nd quarter. Hamlin Capital Management LLC now owns 2,066,689 shares of the company’s stock valued at $82,688,000 after buying an additional 295,930 shares in the last quarter. 7.54% of the stock is owned by hedge funds and other institutional investors.
Sanofi Company Profile
Sanofi provides therapeutic solutions. It offers Cerezyme and Cerdelga for Gaucher disease, Myozyme and Lumizyme for Pompe disease, Fabrazyme for Fabry disease, and Aldurazyme for mucopolysaccharidosis Type 1; Aubagio, an oral immunomodulatory; and Lemtrada, a monoclonal antibody to treat multiple sclerosis.
Read More: Terms to Better Understand Call Options
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with MarketBeat.com's FREE daily email newsletter.